Beijing Medical and Health Industry Investment Fund
北京市医药健康产业投资基金
Beijing Medical and Health Industry Investment Fund (北京市医药健康产业投资基金) is one of Beijing's "eight industry guidance funds" — the eight sector-specific government funds launched with a combined initial scale of RMB 100 billion, overseen by Beijing State-Owned Capital Operation and Management's guidance-fund arm and each handed to a market-oriented GP; the healthcare fund is managed by CBC Group (康桥资本) . Per a 暗涌Waves piece citing Beijing Guoguan's general manager Guo Chuan, by end-2024 the eight funds together had approved 167 projects totaling about RMB 17 billion, with roughly RMB 12.7 billion actually deployed across 135 of them .
The fund has been an active direct investor rather than just an LP vehicle: it co-led METiS Pharmaceuticals' RMB 400 million Series D alongside the Daxing district fund (per 源码资本, Aug 2025) , led Qihe Biotech's RMB 200 million+ Series A in late 2024 , joined DeepWise's RMB 800 million+ Series C and CytoNiche's Series B+ , and co-led both tranches of Oricell Therapeutics' Series C and its $110 million pre-IPO round with Qiming and Vivo Capital in early 2026 . Note that the most specific deal records here come from portfolio-side announcements by partner institutions, so founding date and fund size for this vehicle itself aren't detailed in elsewhere's corpus.
AI-generated — may contain errors, please verify.
Coverage
Inno Pharmaceuticals Completes Nearly RMB 800 Million Series D Funding to Accelerate Global Multicenter Clinical Development of Precision Targeted Drugs
The company has pioneered a proprietary active-targeting liposomal drug delivery platform, underpinning an innovative drug pipeline that spans multiple serious disease areas, including cardiovascular and cerebrovascular diseases and glioblastoma.
OriCell Therapeutics Announces $110 Million Pre-IPO Round, Co-Led by Qiming Venture Partners
Global leader in innovative tumor immunotherapy
Oricell Therapeutics Closes First Tranche of $70M Series C to Accelerate Global Development of Solid Tumor CAR-T Therapies
A global leader in innovative tumor immunotherapy
MaKe | DeepWise Completes Over 800 Million Yuan Series C Financing
The completion of this financing round marks a solid step forward for DeepWise in its journey to build a next-generation intelligent engine for scientific discovery.
From Two Rounds in Six Months to a $400M Series D: 10 Companies Announce New Funding | FreeS Family Funding News Vol.24
Looking forward to working alongside more outstanding founders.
3D Cell Manufacturing Platform Huaxin Biotech Closes Series B+ Round to Accelerate Cell Therapy Commercialization for Global Clients
Ushering in the 2.0 era of cell-based industrialization.
MaHui Spotlight | MaHui Member METiS Pharmaceuticals Closes RMB 400 Million Series D to Help Build Beijing's Biotech "New Engine"
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Qihe Biotech Closes Over RMB 200 Million Series A to Accelerate Gene Editing R&D and Commercialization
Develop novel gene-editing technologies to create exceptional biological traits and products.
